Watch the video recording on YouTube: https://youtu.be/BM6x59oMnKg?si=qF0xDvgUMvU60ctP
2025 has been the start of a bull period for psychedelic medicine.
Psychedelic Biotechs like GH Research, Compass Pathways and Lykos Therapeutics are releasing impressive, late stage clinical trial data
Capital is following the data: Cybin just raised $500M and Johnson and Johnson's Ketamine-inspired antidepressant Spravato broke $1B+ / year of topline.
A new administration seems surprisingly interested in accelerating the FDA approval of psychedelics as treatments for mental health disorders
Learn how top VCs and LPs are mapping and allocating to this exciting space in this special event designed for family offices and HNWIs.
You will learn:
The contrasting approaches that biotech and pharma are taking to commercialize psychedelic medicine
Where we see the highest-leverage points for investing
Lessons from past failures
And of course there will be plenty of time for interaction and Q&A
This event is run by Brom Rector and Sam Tabone of XEIA, a venture capital fund that invests in "Human 3 - the next epoch of human health, wellbeing and performance". As part of their Human 3 thesis, they have invested in 8 psychedelic medicine companies from pre-seed to pre-IPO.